Susan D. Richman

Mismatch Repair Status and <i>BRAF</i> Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

Sabine Venderbosch, Irıs D. Nagtegaal, Tim Maughan et al. · Clinical Cancer Research · 2014 · 725 citations · Full text

Value of Mismatch Repair, <i>KRAS</i> , and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

Gordon Hutchins, Katie Southward, Kelly Handley et al. · Journal of Clinical Oncology · 2011 · 675 citations · Full text

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Susan D. Richman, Philip Chambers, Faye Elliott et al. · Journal of Clinical Oncology · 2009 · 567 citations

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

Sarah Brown, Gary Middleton, Tim Maughan et al. · The Lancet Oncology · 2013 · 388 citations · Full text

Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning

Amelie Echle, Heike I. Grabsch, Philip Quirke et al. · Gastroenterology · 2020 · 356 citations · Full text